These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23095811)

  • 1. Animal models for human polycystic kidney disease.
    Nagao S; Kugita M; Yoshihara D; Yamaguchi T
    Exp Anim; 2012; 61(5):477-88. PubMed ID: 23095811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycystic kidney disease: etiology, pathogenesis, and treatment.
    Martinez JR; Grantham JJ
    Dis Mon; 1995 Nov; 41(11):693-765. PubMed ID: 7587886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Jeremiah Metzger Lecture. Polycystic kidney disease: old disease in a new context.
    Grantham JJ
    Trans Am Clin Climatol Assoc; 2002; 113():211-24; discussion 224-6. PubMed ID: 12053711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The master regulators Myc and p53 cellular signaling and functions in polycystic kidney disease.
    Kurbegovic A; Trudel M
    Cell Signal; 2020 Jul; 71():109594. PubMed ID: 32145315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease.
    Liebau MC; Serra AL
    Pediatr Nephrol; 2013 Sep; 28(9):1771-83. PubMed ID: 23239392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical practice guidelines for polycystic kidney diseases].
    Writing Group For Practice Guidelines For Diagnosis And Treatment Of Genetic Diseases Medical Genetics Branch Of Chinese Medical Association ; Xu D; Mei C
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Mar; 37(3):277-283. PubMed ID: 32128744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of laminin-332 promotes cell proliferation and cyst growth in ARPKD.
    Vijayakumar S; Dang S; Marinkovich MP; Lazarova Z; Yoder B; Torres VE; Wallace DP
    Am J Physiol Renal Physiol; 2014 Mar; 306(6):F640-54. PubMed ID: 24370592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polycystic kidney diseases: molecular genetics and counselling].
    Lespinasse J; Fourcade J; Schir F
    Nephrol Ther; 2006 Jul; 2(3):120-6. PubMed ID: 16890136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine models of polycystic kidney disease: molecular and therapeutic insights.
    Guay-Woodford LM
    Am J Physiol Renal Physiol; 2003 Dec; 285(6):F1034-49. PubMed ID: 14600027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1.
    Alcalay NI; Sharma M; Vassmer D; Chapman B; Paul B; Zhou J; Brantley JG; Wallace DP; Maser RL; Vanden Heuvel GB
    Am J Physiol Renal Physiol; 2008 Dec; 295(6):F1725-34. PubMed ID: 18829740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in understanding the pathogenesis of polycystic kidney disease: therapeutic implications.
    Cowley BD
    Drugs; 2004; 64(12):1285-94. PubMed ID: 15200344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders.
    Nagao S; Yamaguchi T
    Curr Mol Pharmacol; 2012 Jun; 5(2):292-300. PubMed ID: 22122459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant Regulation of Notch3 Signaling Pathway in Polycystic Kidney Disease.
    Idowu J; Home T; Patel N; Magenheimer B; Tran PV; Maser RL; Ward CJ; Calvet JP; Wallace DP; Sharma M
    Sci Rep; 2018 Feb; 8(1):3340. PubMed ID: 29463793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic kidney disease and therapeutic approaches.
    Park EY; Woo YM; Park JH
    BMB Rep; 2011 Jun; 44(6):359-68. PubMed ID: 21699747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycystic kidney disease in Sprague-Dawley rats.
    Shoieb A; Shirai N
    Exp Toxicol Pathol; 2015; 67(5-6):361-4. PubMed ID: 25753522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and Severe Polycystic Kidney Disease and Related Ciliopathies: An Emerging Field of Interest.
    Bergmann C
    Nephron; 2019; 141(1):50-60. PubMed ID: 30359986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycystic kidney disease.
    Bergmann C; Guay-Woodford LM; Harris PC; Horie S; Peters DJM; Torres VE
    Nat Rev Dis Primers; 2018 Dec; 4(1):50. PubMed ID: 30523303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney: polycystic kidney disease.
    Paul BM; Vanden Heuvel GB
    Wiley Interdiscip Rev Dev Biol; 2014; 3(6):465-87. PubMed ID: 25186187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
    Holditch SJ; Schreiber CA; Harris PC; LaRusso NF; Ramirez-Alvarado M; Cataliotti A; Torres VE; Ikeda Y
    Kidney Int; 2017 Sep; 92(3):657-668. PubMed ID: 28416225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies to slow polycystic kidney disease.
    Torres VE
    Nephron Exp Nephrol; 2004; 98(1):e1-7. PubMed ID: 15361692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.